{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T16:38:55Z","timestamp":1772555935137,"version":"3.50.1"},"reference-count":22,"publisher":"Oceanside Publications Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Rapid drug desensitizations (RDD) provide a means for patients with a history of acute hypersensitivity reactions (HSR) to platinum-based chemotherapeutics to continue their first-line oncologic treatment. Approximately one third of RDDs have been associated with\n breakthrough reactions (BTR) but identifying which patients are at risk is challenging.  <jats:bold>Objective:<\/jats:bold> The objective was to identify factors predictive of patients at risk of developing BTR during their initial RDD.  <jats:bold>Methods:<\/jats:bold> Forty-three patients who developed\n HSRs to a platinum drug and subsequently underwent RDDs were included for analysis. A retrospective manual chart review was performed to obtain demographics and information with regard to oncologic history, incident HSR, and RDD. The severity of HSRs and BTRs was determined by using the Brown\n criteria.  <jats:bold>Results:<\/jats:bold> BTRs developed in 37% of patients during their initial RDD. Compared with those who tolerated RDDs, the patients who developed BTRs were significantly more likely to have positive allergy skin test results with a platinum drug (100%) than those who tolerated\n their RDD (47%, p = 0.01). The median (interquartile range) time between incident HSR and initial RDD was significantly shorter among patients who developed BTRs (31 days [21\u201049 days]) than those who did not develop BTRs (46 days [28\u2010826 days]) (p\u2009=\u20090.04). Only\n 46% of patients with severe incident HSRs developed a BTR. However, severe BTRs occurred only in patients who had severe incident HSRs (p\u2009=\u20090.02).  <jats:bold>Conclusion:<\/jats:bold> Severe clinical signs and symptoms of incident HSRs do not always predict if BTRs will occur during\n initial RDDs. However, patients with severe BTRs are more likely to have had a severe incident HSR.<\/jats:p>","DOI":"10.2500\/aap.2025.46.250038","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:34:02Z","timestamp":1751934842000},"page":"328-334","source":"Crossref","is-referenced-by-count":3,"title":["Clinical predictors of breakthrough reactions during initial rapid drug desensitizations to platinum chemotherapeutics"],"prefix":"10.2500","volume":"46","author":[{"given":"Taylor R.","family":"Knowles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharine J.","family":"Nehme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So Lim","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol A.","family":"Saltoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anju T.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Whitney W.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1355","reference":[{"key":"B1"},{"key":"B2"},{"key":"B3","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jaip.2015.07.003","article-title":"Skin testing in the evaluation and management of carboplatin-related hypersensitivity reactions","volume":"3","author":"Lax","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B4","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA Adverse Event Reporting System (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B5","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2008.02.044","article-title":"Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases","volume":"122","author":"Castells","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jaci.2022.08.028","article-title":"Drug allergy: a 2022 practice parameter update","volume":"150","author":"Khan","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/all.15113","article-title":"Hypersensitivity reactions to chemotherapy: an EAACI Position Paper","volume":"77","author":"Pagani","year":"2022","journal-title":"Allergy"},{"key":"B8","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jaip.2015.12.019","article-title":"Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies","volume":"4","author":"Sloane","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.anai.2019.05.007","article-title":"Breakthrough reactions during rapid drug desensitization: clinical outcome and risk factors","volume":"123","author":"Kang","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2024.12.021","article-title":"Risk factors of hypersensitivities to carboplatin: a systematic review and meta-analysis","volume":"13","author":"Jang","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B11","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1007\/s10147-021-02034-3","article-title":"Meta-analysis of risk factors associated with oxaliplatin hypersensitivity reactions in cancer patients","volume":"26","author":"Zhu","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"B12","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jaci.2009.02.042","article-title":"Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management","volume":"123","author":"Hesterberg","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jaci.2011.10.010","article-title":"A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions","volume":"129","author":"Patil","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.anai.2015.07.017","article-title":"Risk-stratification protocol for carboplatin and oxaliplatin hypersensitivity: repeat skin testing to identify drug allergy","volume":"115","author":"Wang","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.jaip.2019.12.032","article-title":"Allergy evaluation of hypersensitivity to platinum salts and taxanes: a six-year experience","volume":"8","author":"Pradelli","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaci.2004.04.029","article-title":"Clinical features and severity grading of anaphylaxis","volume":"114","author":"Brown","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jaci.2024.03.010","article-title":"Prevention of allergic reactions during oxaliplatin desensitization through inhibition of Bruton tyrosine kinase","volume":"154","author":"Erickson","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/all.15940","article-title":"Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: phenotypes, endotypes, and management with desensitization","volume":"79","author":"Jimenez-Rodriguez","year":"2024","journal-title":"Allergy"},{"key":"B19","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.jaip.2020.02.013","article-title":"Endophenotyping oxaliplatin hypersensitivity: personalizing desensitization to the atypical platin","volume":"8","author":"Silver","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B20","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jaip.2016.11.006","article-title":"Basophil activation test is a relevant biomarker of the outcome of rapid desensitization in platinum compounds-allergy","volume":"5","author":"Giavina-Bianchi","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B21","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jaci.2023.08.018","article-title":"United States Drug Allergy Registry (USDAR) grading scale for immediate drug reactions","volume":"152","author":"Khan","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B22","doi-asserted-by":"crossref","first-page":"100472","DOI":"10.1016\/j.waojou.2020.100472","article-title":"World Allergy Organization anaphylaxis guidance 2020","volume":"13","author":"Cardona","year":"2020","journal-title":"World Allergy Organ J"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2025\/00000046\/00000004\/art00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T04:32:55Z","timestamp":1752553975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2025.46.250038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7,1]]}},"alternative-id":["1088-5412(20250701)46:4L.328;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2025.46.250038","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}